Transdermal microconduits by microscission for drug delivery and sample acquisition
Background Painless, rapid, controlled, minimally invasive molecular transport across human skin for drug delivery and analyte acquisition is of widespread interest. Creation of microconduits through the stratum corneum and epidermis is achieved by stochastic scissioning events localized to typicall...
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
BioMed Central Ltd
2010
|
| Online Access: | http://hdl.handle.net/1721.1/58737 https://orcid.org/0000-0002-9016-5962 |
| _version_ | 1811086319683633152 |
|---|---|
| author | Gonzalez, Salvador Herndon, Terry O. Gowrishankar, Thiruvallur R. Anderson, R. Rox Weaver, James C. |
| author2 | Harvard University--MIT Division of Health Sciences and Technology |
| author_facet | Harvard University--MIT Division of Health Sciences and Technology Gonzalez, Salvador Herndon, Terry O. Gowrishankar, Thiruvallur R. Anderson, R. Rox Weaver, James C. |
| author_sort | Gonzalez, Salvador |
| collection | MIT |
| description | Background Painless, rapid, controlled, minimally invasive molecular transport across human skin for drug delivery and analyte acquisition is of widespread interest. Creation of microconduits through the stratum corneum and epidermis is achieved by stochastic scissioning events localized to typically 250 μm diameter areas of human skin in vivo. Methods Microscissioning is achieved by a limited flux of accelerated gas: 25 μm inert particles passing through the aperture in a mask held against the stratum corneum. The particles scize (cut) tissue, which is removed by the gas flow with the sensation of a gentle stream of air against the skin. The resulting microconduit is fully open and may be between 50 and 200 μm deep. Results In vivo adult human tests show that microconduits reduce the electrical impedance between two ECG electrodes from approximately 4,000 Ω to 500 Ω. Drug delivery has been demonstrated in vivo by applying lidocaine to a microconduit from a cotton swab. Sharp point probing demonstrated full anaesthesia around the site within three minutes. Topical application without the microconduit required approximately 1.5 hours. Approximately 180 μm deep microconduits in vivo yielded blood sample volumes of several μl, with a faint pricking sensation as blood enters tissue. Blood glucose measurements were taken with two commercial monitoring systems. Microconduits are invisible to the unaided eye, developing a slight erythematous macule that disappears over days. Conclusion Microscissioned microconduits may provide a minimally invasive basis for delivery of any size molecule, and for extraction of interstitial fluid and blood samples. Such microconduits reduce through-skin electrical impedance, have controllable diameter and depth, are fully open and, after healing, no foreign bodies were visible using through-skin confocal microscopy. In subjects to date, microscissioning is painless and rapid. |
| first_indexed | 2024-09-23T13:24:17Z |
| format | Article |
| id | mit-1721.1/58737 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T13:24:17Z |
| publishDate | 2010 |
| publisher | BioMed Central Ltd |
| record_format | dspace |
| spelling | mit-1721.1/587372022-10-01T15:03:52Z Transdermal microconduits by microscission for drug delivery and sample acquisition Gonzalez, Salvador Herndon, Terry O. Gowrishankar, Thiruvallur R. Anderson, R. Rox Weaver, James C. Harvard University--MIT Division of Health Sciences and Technology Herndon, Terry O. Gonzalez, Salvador Gowrishankar, Thiruvallur R. Anderson, R. Rox Weaver, James C. Background Painless, rapid, controlled, minimally invasive molecular transport across human skin for drug delivery and analyte acquisition is of widespread interest. Creation of microconduits through the stratum corneum and epidermis is achieved by stochastic scissioning events localized to typically 250 μm diameter areas of human skin in vivo. Methods Microscissioning is achieved by a limited flux of accelerated gas: 25 μm inert particles passing through the aperture in a mask held against the stratum corneum. The particles scize (cut) tissue, which is removed by the gas flow with the sensation of a gentle stream of air against the skin. The resulting microconduit is fully open and may be between 50 and 200 μm deep. Results In vivo adult human tests show that microconduits reduce the electrical impedance between two ECG electrodes from approximately 4,000 Ω to 500 Ω. Drug delivery has been demonstrated in vivo by applying lidocaine to a microconduit from a cotton swab. Sharp point probing demonstrated full anaesthesia around the site within three minutes. Topical application without the microconduit required approximately 1.5 hours. Approximately 180 μm deep microconduits in vivo yielded blood sample volumes of several μl, with a faint pricking sensation as blood enters tissue. Blood glucose measurements were taken with two commercial monitoring systems. Microconduits are invisible to the unaided eye, developing a slight erythematous macule that disappears over days. Conclusion Microscissioned microconduits may provide a minimally invasive basis for delivery of any size molecule, and for extraction of interstitial fluid and blood samples. Such microconduits reduce through-skin electrical impedance, have controllable diameter and depth, are fully open and, after healing, no foreign bodies were visible using through-skin confocal microscopy. In subjects to date, microscissioning is painless and rapid. Massachusetts Institute of Technology Lincoln Laboratory National Institutes of Health (U.S.) Massachusetts General Hospital CIMIT: Center for Integration of Medicine and Innovative Technology 2010-09-28T19:19:10Z 2010-09-28T19:19:10Z 2004-04 2003-10 2010-09-03T16:22:52Z Article http://purl.org/eprint/type/JournalArticle 1741-7015 http://hdl.handle.net/1721.1/58737 Herndon, Terry et al. “Transdermal microconduits by microscission for drug delivery and sample acquisition.” BMC Medicine 2.1 (2004): 12. PMID: 15090063 https://orcid.org/0000-0002-9016-5962 en http://dx.doi.org/10.1186/1741-7015-2-12 BMC Medicine Creative Commons Attribution Herndon et al.; licensee BioMed Central Ltd. application/pdf BioMed Central Ltd BioMed Central Ltd |
| spellingShingle | Gonzalez, Salvador Herndon, Terry O. Gowrishankar, Thiruvallur R. Anderson, R. Rox Weaver, James C. Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title | Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title_full | Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title_fullStr | Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title_full_unstemmed | Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title_short | Transdermal microconduits by microscission for drug delivery and sample acquisition |
| title_sort | transdermal microconduits by microscission for drug delivery and sample acquisition |
| url | http://hdl.handle.net/1721.1/58737 https://orcid.org/0000-0002-9016-5962 |
| work_keys_str_mv | AT gonzalezsalvador transdermalmicroconduitsbymicroscissionfordrugdeliveryandsampleacquisition AT herndonterryo transdermalmicroconduitsbymicroscissionfordrugdeliveryandsampleacquisition AT gowrishankarthiruvallurr transdermalmicroconduitsbymicroscissionfordrugdeliveryandsampleacquisition AT andersonrrox transdermalmicroconduitsbymicroscissionfordrugdeliveryandsampleacquisition AT weaverjamesc transdermalmicroconduitsbymicroscissionfordrugdeliveryandsampleacquisition |